Top Medical Searches

Norway to buy Biogen’s Spinraza medicine: broadcaster NRK

OSLO (Reuters) – Norwegian authorities will buy the rare-disease treatment Spinraza for patients from U.S. drugmaker Biogen Inc at a cost of 7 million Norwegian crowns ($880,381.33) per year per patient, public broadcaster NRK reported on Monday.

 Read more…

Be Sociable, Share!
February 12th, 2018 Posted in Drug
Copyright 2008 © Drugs and Diseases. Developed by Axilosoft
Home | About Us | Privacy Policy | Contact Us